Anti-IL2 Antibody Rezpegaldesleukin Shows Promise in Atopic Dermatitis and Comorbid Asthma (Possible Dual Indication)
Early Phase 2b data (REZOLVE-AD trial, NCT06136741) support rezpegaldesleukin (rezpeg), a first-in-class IL-2 agonist that selectively expands regulatory T cells to restore immune balance.
In this randomized, double-blind, placebo-controlled study of adults with moderate-to-severe atopic dermatitis (AD), the highest dose (24 µg/kg every 2 weeks for 16 weeks) delivered significant improvements vs placebo:
Among the 99 participants with comorbid asthma (25 uncontrolled at baseline), the same dose improved Asthma Control Questionnaire-5 (ACQ-5) scores significantly.
Safety was favorable: most adverse events were mild/moderate. Injection-site reactions were common (69.7% vs 4.1% placebo), with low rates of eosinophilia, pyrexia, headache.
These interim findings, presented at Maui Derm 2026, support advancing rezpegaldesleukin as a potential novel biologic for AD—and possibly asthma—by targeting immune regulation rather than broad suppression. Larger Phase 3 studies are needed to confirm efficacy and long-term safety.
Atopic dermatitis maintenance (click to enlarge the image).
References:
https://www.dermatologyadvisor.com/news/early-findings-support-efficacy-rezpegaldesleukin-ad-asthma/